{"name":"Genfit","slug":"genfit","ticker":"GNFT","exchange":"NASDAQ","domain":"genfit.com","description":"Genfit is a biopharmaceutical company focused on the development of treatments for liver diseases. The company's lead product, Elafibranor, is being developed for the treatment of primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). Genfit has a strong pipeline of products in various stages of development, including GFT505, a potential treatment for NASH. The company is well-positioned to capitalize on the growing market for liver disease treatments.","hq":"Lille, France","founded":0,"employees":"","ceo":"Pascal Prigent","sector":"Hepatology / Liver Disease","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"$240M","metrics":{"revenue":95000000,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2030-06-01","label":"Elafibranor patent cliff ($1.2B at risk)","drug":"Elafibranor","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"14C-labelled GFT505 120 mg","genericName":"14C-labelled GFT505 120 mg","slug":"14c-labelled-gft505-120-mg","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"14C-labelled GFT505 120 mg","genericName":"14C-labelled GFT505 120 mg","slug":"14c-labelled-gft505-120-mg","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-28","type":"earnings","headline":"Genfit Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Genfit reported its financial results for the fourth quarter and full year 2023, with a net loss of €43.8 million for the year.","drugName":"","sentiment":"neutral"},{"date":"2023-06-01","type":"deal","headline":"Genfit Announces Collaboration with the University of California, San Francisco","summary":"Genfit announced a collaboration with the University of California, San Francisco to develop new treatments for liver diseases.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiY0FVX3lxTFBZSi1yYUc5aFZoT01aajYzNWExWFJ3NU9pQmVtdGk1Ulltd0k2UjJJWVNCUDVBZ3piVE1kYXNRVnJodzcwSm5OVUVRVUFhTFIySXJLOVlPUnV2bDJWdUxlck1CWQ?oc=5","date":"2026-04-02","type":"pipeline","source":"ChartMill","summary":"GNFT.PA Stock Price, Quote & Chart | GENFIT (EPA:GNFT) - ChartMill","headline":"GNFT.PA Stock Price, Quote & Chart | GENFIT (EPA:GNFT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxQOGxJTHQzejhJSkhWMU9oalZsODZad0ZrclhNU20xUjB5dF81dFd4UzhoNFFyem9zYmU5ampmdlM5Y1hvTTlIdUFRU3g4WVZieUR5a2UtNEhPWk5JazhXLW1LODVBVW4wdGhKTlctUE5UNWstLW5JWHQxV3NodVA1R25oX2VId0JqUHBrSVd3?oc=5","date":"2026-02-12","type":"pipeline","source":"Seeking Alpha","summary":"Genfit adds $20M as Ipsen posts strong Iqirvo sales (GNFTY) - Seeking Alpha","headline":"Genfit adds $20M as Ipsen posts strong Iqirvo sales (GNFTY)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQM3V4M2JqbUFPZV84WWlxdERVZDRiLW5pZ0VvZDZxZmx5c3dIOE9vbV9uVmdRMHBQWVlPZlZKVGJYYk5vYTFUekI1X3NVNWJScmtzZmtFT1hubjlaWW55WTJJdVlqcDloVi1PcnpoVWVnYXFDbm1tajJicEs1dEN1WnFNMVItLWc?oc=5","date":"2025-10-09","type":"deal","source":"Seeking Alpha","summary":"Viking, Genfit, Sagimet jump on Novo- Akero deal (AKRO:NASDAQ) - Seeking Alpha","headline":"Viking, Genfit, Sagimet jump on Novo- Akero deal (AKRO:NASDAQ)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-09-23","type":"pipeline","source":"simplywall.st","summary":"These Analysts Just Made An Downgrade To Their Genfit S.A. (EPA:GNFT) EPS Forecasts - simplywall.st","headline":"These Analysts Just Made An Downgrade To Their Genfit S.A. (EPA:GNFT) EPS Forecasts","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPWVd2d2NfZjJ6RXNMOE1mQlUwVDhXRmFDaDNrY1hNMGVYZHJfVmZrUDZ1V1M0NjlCMk9rVHBQTW8wQTJPVFp5M1FkcS1aSk1KMVpERmtDVHl2a2Vsb2poaHpyWm1Bb0pJeV9ZanFZN2VCRmNmTkxja0wxVFBVMWNaTXZtenBtZGVwS3FfcWdPX3Q3alNVeGhYYk5ZdHhUUlkzOWpHaA?oc=5","date":"2025-05-12","type":"pipeline","source":"Seeking Alpha","summary":"Genfit: Iqirvo's Success Can't Outweigh ACLF Pipeline Risks (NASDAQ:GNFT) - Seeking Alpha","headline":"Genfit: Iqirvo's Success Can't Outweigh ACLF Pipeline Risks (NASDAQ:GNFT)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFB2U0VXRkEtMm9Eejg4ek5fWFFQTFQtNnhkT0JoMjJ2VFVvTHRIOWZTWTYwYVBUTUNkM2l2eDFHUldlelpjZFpCNlA2ekVCbFpTamU4?oc=5","date":"2025-04-25","type":"pipeline","source":"Stock Titan","summary":"GNFT Stock Price, News & Analysis | Genfit S.A. - Stock Titan","headline":"GNFT Stock Price, News & Analysis | Genfit S.A.","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivAFBVV95cUxQRlc1V2hsckFzVVRnZVl1bnktVzBxRWJfQ1J3V3g1cXFxMk9OMmFRQTlrSEFfN21YNjJnTW1McFI1LWExN1NiM0d4anE4eG43X0hPcC1raTZURWFndDJYQk02Um1Zc0x2dmJXdW5saTA5eFFsZVNCekwzYms2anhQODlmSWdpcFpXVkhGaWItdmlfWDU4MUgwNHlHbjR1WU01ZDlOeDdQTG83MUpZeUVxMDZXSUZkR3ltUm5FXw?oc=5","date":"2024-06-11","type":"regulatory","source":"Reuters","summary":"US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug - Reuters","headline":"US FDA grants accelerated approval to Genfit and Ipsen's liver disease drug","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOYkpESVNfRUFURk5RWk54bTJWUXV3RnpmMmtlQ1ozTVFVQjd2Z2ZkRXZCWFhVSVNqbnFUY1RBSWk2VGtCVXNSdDlNV1hSNl9XdS1NcEc3V1phdGNzS3ZIMmdIR09pcjN3c3ItTTMycVdfZE1yaXE0a3BzRVp2d2dzZTMxTnhPbkZfSXRVdDczd1llVEgxeWVNX0V4cU84S1dSTnY3ZFJDb3g4OGM?oc=5","date":"2020-09-02","type":"earnings","source":"Barron's","summary":"Intercept Pharmaceuticals Will Lay Off a Quarter of Its Staff as NASH Dream Fades - Barron's","headline":"Intercept Pharmaceuticals Will Lay Off a Quarter of Its Staff as NASH Dream Fades - Barron's","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMid0FVX3lxTFB3dTd6aUxBZlpxY19OaVVLODZWd2lhaG9zTGtIeWFFeEMybE9xcUNKa2NOODY0NzhzcVZTc0hhd3dhRVMtR3JiR0Rud0piVVNKTEI3cHQxaXB1YUZBYVZBNDRxdzhibUN4NUthdkszcVg0Y3puSG0w?oc=5","date":"2020-02-10","type":"trial","source":"proactiveinvestors.com","summary":"Genfit SA expecting Phase 3 results of its NASH therapy by 1Q - proactiveinvestors.com","headline":"Genfit SA expecting Phase 3 results of its NASH therapy by 1Q","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiTkFVX3lxTE84OUJYSXpMYkxpMWRmTjFfcUpXVkltT2RhOGhRZ05la2ZadTVZMTJoSmpRU0thTE5WMTA1djFfOXhpVmNKQlpvNF9vMThvdw?oc=5","date":"2019-05-12","type":"pipeline","source":"eToro","summary":"GNFT.PA Stock Price | Analyst Target 15.00 & Consensus - eToro","headline":"GNFT.PA Stock Price | Analyst Target 15.00 & Consensus","sentiment":"neutral"}],"patents":[{"drugName":"Elafibranor","drugSlug":"elafibranor","patentNumber":"","type":"Patent Cliff","expiryDate":"2030-06-01","territory":"US","annualRevenue":1200000000}],"drugCount":1,"phaseCounts":{"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Gilead Sciences","Intercept Pharmaceuticals","Madrigal Pharmaceuticals"],"therapeuticFocus":["Hepatology","Liver Disease"],"financials":null,"yahoo":null}